Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Picard

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Lancet (London, England)|July 21, 1990
AIDS vaccine therapy: phase I trialO Picard, P Giral, M C Defer, et al.
AIDS (London, England)|March 1, 1995
A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDSJ Gozlan, M el Amrani, M Baudrimont, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virusA Willer, A Achour, J P Mbika, et al.
Gut|October 4, 2008
Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurinesS Ben-Horin, I Goldstein, E Fudim, et al.
Annales De Dermatologie Et De Venereologie|January 1, 1982
[New forms of Kaposi's disease occurring in the young subject]I Gorin, O Picard, C Frances, et al.
Journal of Human Virology|April 9, 1999
AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparationsP Hermans, N Clumeck, O Picard, et al.
L'Encephale|November 14, 2006
[Health related quality of life and lipodystrophy syndrome among HIV-infected patients]M Préau, A-D Bouhnik, B Spire, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2018
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factorS Ben-Horin, B Ungar, U Kopylov, et al.
Alimentary Pharmacology & Therapeutics|February 1, 2012
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBDS Ben-Horin, Y Mazor, H Yanai, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Lancet (London, England)|July 21, 1990
AIDS vaccine therapy: phase I trialO Picard, P Giral, M C Defer, et al.
AIDS (London, England)|March 1, 1995
A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDSJ Gozlan, M el Amrani, M Baudrimont, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virusA Willer, A Achour, J P Mbika, et al.
Gut|October 4, 2008
Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurinesS Ben-Horin, I Goldstein, E Fudim, et al.
Annales De Dermatologie Et De Venereologie|January 1, 1982
[New forms of Kaposi's disease occurring in the young subject]I Gorin, O Picard, C Frances, et al.
Journal of Human Virology|April 9, 1999
AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparationsP Hermans, N Clumeck, O Picard, et al.
L'Encephale|November 14, 2006
[Health related quality of life and lipodystrophy syndrome among HIV-infected patients]M Préau, A-D Bouhnik, B Spire, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2018
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factorS Ben-Horin, B Ungar, U Kopylov, et al.
Alimentary Pharmacology & Therapeutics|February 1, 2012
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBDS Ben-Horin, Y Mazor, H Yanai, et al.
Pageof 8